ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 136 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 4.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $4,275,558 | -12.2% | 448,642 | +1.4% | 0.01% | -17.6% |
Q1 2023 | $4,867,269 | -2.1% | 442,479 | +31.8% | 0.02% | -5.6% |
Q4 2022 | $4,969,633 | -61.5% | 335,786 | -50.3% | 0.02% | -28.0% |
Q3 2022 | $12,902,440 | +35.4% | 675,190 | +51.0% | 0.02% | +38.9% |
Q2 2022 | $9,531,598 | -30.3% | 447,264 | -37.0% | 0.02% | -5.3% |
Q1 2022 | $13,672,202 | +122.5% | 709,886 | +139.6% | 0.02% | +18.8% |
Q4 2021 | $6,144,000 | -0.7% | 296,253 | +14.3% | 0.02% | -5.9% |
Q3 2021 | $6,190,000 | -53.4% | 259,084 | -46.8% | 0.02% | -10.5% |
Q2 2021 | $13,282,000 | +104.5% | 486,728 | +116.8% | 0.02% | -5.0% |
Q1 2021 | $6,496,000 | – | 224,548 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
Two Seas Capital LP | 164,807 | $875,125 | 0.18% |